AstriVax Therapeutics SA
17.1 FTEAstriVax Therapeutics reported total assets of €12.5m at the end of the 2025 financial year (annual accounts filed with the NBB on 21 May 2026), with 17.1 full-time equivalents.
By total assets for 2025, AstriVax Therapeutics ranks among the 100 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of AstriVax Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity -27 % Total assets -37 % Headcount (avg FTE) +37 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
AstriVax Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 21 May 2026
- Year ended 31 Dec 2024filed on 23 Jul 2025
- Year ended 31 Dec 2023filed on 26 Jun 2024
AstriVax Therapeutics's financial analysis
- Solvency85.3%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of AstriVax Therapeutics
12 active director(s) in the register.
and 6 more
AstriVax Therapeutics's shareholders and holdings →AstriVax Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0787.990.881
- VAT number
- BE0787990881
- Peppol
- Registered · 0208:0787990881 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 04 Jul 2022
- Registered office
- 3001 Leuven
- Size
- Small · 17.1 FTE
- Latest accounts
- 2025 · filed on 21 May 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
AstriVax Therapeutics (SA) has been based in Leuven since 2022, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €7.66m and equity of €10.7m; its revenue is not published. With 17.1 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 85.3%, above the median of its sector (61.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to AstriVax Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- OSIVAX Belgique Research and experimental development on natural sciences and engineering Liège · balance sheet €17.0m
- The Akkermansia Company Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €16.9m
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
- Aquilon Pharmaceuticals Research and experimental development on natural sciences and engineering Seraing · balance sheet €11.1m
- Augustine Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €30.9m
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
- Aboleris Holdco Research and experimental development on natural sciences and engineering Charleroi · balance sheet €14.8m
Frequently asked questions about AstriVax Therapeutics
What is the revenue of AstriVax Therapeutics?
AstriVax Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of AstriVax Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0787990881 for AstriVax Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0787.990.881.
Where is the registered office of AstriVax Therapeutics?
According to the CBE register, the registered office of AstriVax Therapeutics is in 3001 Leuven.
What is the equity of AstriVax Therapeutics?
At the close of the 2025 financial year, the equity of AstriVax Therapeutics amounts to 10,690,260 €, a solvency of 85.3% of total assets.
How many people work at AstriVax Therapeutics?
17.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages AstriVax Therapeutics?
The register lists 12 active mandates at AstriVax Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is AstriVax Therapeutics within its sector?
By total assets for 2025, AstriVax Therapeutics ranks among the 100 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of AstriVax Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →